This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.
April 20, 2022
Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL:https://www.modalistx.com/en/
Representative: Haruhiko Morita
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular Dystrophy and the Other Genetic Disorders at the ASGCT Annual Meeting
MDL-101 preclinical data support durability and efficacy of a differentiated precision medicine approach for Congenital Muscular Dystrophy type 1a
Preclinical data demonstrating our proprietary CRISPR based epigenetic modulating technology regulates target gene expression, demonstrating its potential as a therapeutic approach for serious genetic disorders.
20-Apr-2022 TOKYO & Waltham, Mass - Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM epigenetic modulating technology, today announced that six scientific abstracts have been accepted for presentation at the 25th Annual Meeting of the The American Society of Gene & Cell Therapy (ASGCT), being held in Washington D.C. and virtually, May 16-19, 2022. The abstracts present preclinical data from the Company's Congenital Muscular Dystrophy type 1a (CMD1A) and the other rare disease programs in cardiovascular and neuroscience indications, as well as validation of our technology.
Modalis presentations at ASGCT will include preclinical data demonstrating that:
Our single AAV vector system coding dCas9-trans activating domain fusion protein and gRNA targeting LAMA-1 gene (AAV9-CRISPR-GNDM-LAMA1) upregulate LAMA-1 protein to compensate LAMA-2 function in LAMA-2 knock out mice that improved survival, supporting continued development of MDL-101 for the treatment of CMD1A; and
"At ASGCT, we will present preclinical data on MDL-101 that have validate our differentiated therapeutic strategy leveraging our CRISPR-GNDM (guide nucleotide directed modulation) technology for CMD1A which has been an undruggable target. We believe that MDL-101 has the potential to be a life changing gene modulation therapy for CMD1A, and Modalis remains on track to file an IND by end 2023," said Tetsuya Yamagata, M.D. Ph.D., Chief Scientific Officer, Modalis Therapeutics. "We will also share exciting preclinical data showcasing use of our proprietary epigenetic technology to modulate genes to restore expression levels of disease-causing genes. These data reinforce our view that we have a unique epigenetic modulating approach with the potential to treat a wide range of serious genetic disorders that have been unapproachable with other platforms."
The complete list of Modalis Therapeutic presentations is below. Abstracts can be accessed on the ASGCT website and the presentations will be posted on the Modalis website during the conference.
Oral Presentations:
Title: NGS based evaluation of AAV genome integrity for improved production and function Date and Time: 5/16/2022 11:45AM
Session Name: Vector Manufacturing and Engineering 1
Title: Novel single AAV vector treatment for Congenital Muscular Dystrophy type 1A (MDC1A) using CRISPR-GNDMtechnology
Date and Time: 5/18/2022 10:30AM
Session Name: Musculo-skeletal Diseases
Poster Presentations:
Title: Robust suppression of Tau by CRISPR-GNDM system for treatment of Tauopathies Date and Time: 5/16/2022 5:30 PM
Session Name and poster board#: Neurologic Diseases I /M-141
Title: Utilizing CRISPR-GNDM mediated gene activation of the extra-large gene titin for the treatment of dilated cardiomyopathy and other titinopathies
Date and Time: 5/17/2022 5:30 PM
Session Name and poster board#: Cardiovascular and Pulmonary Diseases/Tu-124
Title: Blocking SNHG14/UBE3A-ATS lncRNA Transcription with Dead Cas9 (CRISPR-GNDM) Can Un-Silence Paternal UBE3A in an Angelman Syndrome Mouse Model Date and Time: 5/18/2022 5:30 PM
Session Name and poster board#: Neurologic Diseases III/W-153
Title: Evaluation of Cas9 mediated immune response effect on long term transgene expression in WT mice and NHPs without immune suppression
Date and Time: 5/18/2022 5:30 PM
Session Name and poster board#: Immunological Aspect of Gene Therapy and Vaccine II /W-252
About MDL-101
MDL-101 is an experimental, epigenetic modulation therapy under investigation for the treatment of Congenital Muscular Dystrophy type 1A (CMD1A). MDL-101. MDL-101 is comprised of guide nucleotide targeting LAMA-1 gene, a highly homologous sister gene of the disease-causing gene LAMA-2, enzyme-null Cas9 (dCas9) fused with trans-activating domain driven by a muscle specific promoter and coded in an AAV vector. MDL-101 upregulates LAMA-1 gene products in patient's muscle tissue to compensate loss of function caused by mutation of LAMA-2, and therefore has the potential to provide a one-time, durable treatment benefit for people living with CMD1A.
About Modalis:
Modalis Therapeutics develops precision genetic medicines using epigenetic gene modulation. Modalis is pursuing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or epigenetic editing without the need for double-stranded DNA cleavage, gene editing or base editing. Modalis is initially focusing on genetic disorders caused by loss of gene regulation - resulting in excess or insufficient protein production - by targeting more than 660 genes that are thought to cause human disease as a result of haploinsufficiency. Headquartered in Tokyo with laboratories and facilities in Waltham Massachusetts, the company is listed on Tokyo Stock Exchange's Growth market. For additional information, visitwww.modalistx.com.
Go here to read the rest:
Modalis Therapeutics : to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines at the ASGCT Annual Meeting -...
- VA research will bring precision medicine to mental health - VAntage Point - VAntage Point Blog - June 11th, 2022
- Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and... - June 11th, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 11th, 2022
- UC develops new lung cancer treatment | University Of Cincinnati - University of Cincinnati - June 11th, 2022
- CTGT transactions: Beware of ripples in the safe harbor - JD Supra - June 11th, 2022
- Startup offers genetic testing that promises to predict healthiest embryo - WHYY - June 11th, 2022
- WHRY Funds Studies on Sex Differences in Treating Gastrointestinal Cancers, Bone Health in Transgender Youth, and the Greater Risk for Alzheimer's... - June 11th, 2022
- NIH awards USC more than $16 million for research on vascular dysfunction and Alzheimer's disease | Keck School of Medicine of USC - University of... - June 11th, 2022
- Effect of Metformin on Glycemic Control | DMSO - Dove Medical Press - June 11th, 2022
- Overcoming the Challenges of Cell and Gene Therapy Facilities - Genetic Engineering & Biotechnology News - June 3rd, 2022
- Organoids test gene therapies for Pitt-Hopkins syndrome - Spectrum - June 3rd, 2022
- Gene Therapy Successfully Treats Spinal Cord Injuries Without Side Effects - SciTechDaily - June 3rd, 2022
- The secret to a longer lifespan? Gene regulation holds a clue - EurekAlert - June 3rd, 2022
- Labcorp Expands Access to Comprehensive Genomic Testing Through New Lung Cancer Program - Business Wire - June 3rd, 2022
- Regenerative Medicine Market To Grow At A CAGR Of 11.27% By 2027, Due To Advancements In Cell Biology, Genomics Research, And Gene-Editing Technology... - June 3rd, 2022
- Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision... - June 3rd, 2022
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001 at the 2022 Annual European Hematology Association (EHA)... - June 3rd, 2022
- Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer - DocWire News - June 3rd, 2022
- Winship receives $11 million grant from the National Cancer Institute to improve immunotherapy for lung cancer - EurekAlert - June 3rd, 2022
- Gene Editing Service Market Report 2022-2028 | Keyplayers- Caribou Biosciences, CRISPR Therapeutics, Merck KGa, Editas Medicine The Greater... - June 3rd, 2022
- Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO -... - June 3rd, 2022
- The secret to a longer lifespan? Gene regulation holds a clue - University of Rochester - May 28th, 2022
- Welsh wins 2022 Shaw Prize in Life Sciences and Medicine | Carver College of Medicine - The University of Iowa - May 28th, 2022
- Episode 2: Are We Any Closer to Intestinal Gene Therapy in Crohn's Disease? - Medscape - May 28th, 2022
- Middle East Team Calls for Local Availability of Rapid WGS to Diagnose Severely Ill Infants - GenomeWeb - May 28th, 2022
- The Efficacy of Japanese Herbal Kampo Medicine as an Acute and Prophylactic Medication to Treat Chronic Daily Headache and Medication Overuse... - May 28th, 2022
- Breast cancer in man unexpectedly diagnosed after chest pain - The Columbus Dispatch - May 28th, 2022
- While the fetal clock develops, moms behaviour tells the time - The Daily Star - May 28th, 2022
- Foundation Medicine and Collaborators to Share More Than 20 Abstracts Featuring New Data at the 2022 American Society of Clinical Oncology Annual... - May 28th, 2022
- Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy - BioSpace - May 28th, 2022
- Project SG100K: DNA of 100000 Singaporeans to be mapped to identify new ways to prevent diseases - The Straits Times - May 28th, 2022
- Study reveals potential target for treatment of diseases associated with mitochondrial DNA mutations - EurekAlert - May 28th, 2022
- Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene... - May 28th, 2022
- INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual... - May 28th, 2022
- Outlook on the Single-use Technologies for Biopharmaceuticals Global Market to 2026 - Increasing Demand for Personalized Medicine is Driving Growth -... - May 28th, 2022
- Bostons Seaport gets new cell and gene therapy research center, more to come - Boston Herald - May 17th, 2022
- The CasPlus Gene Editing Platform Technology can Correct Mutations Associated with Duchenne's Muscular Dystrophy and Cystic Fibrosis with High... - May 17th, 2022
- Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene... - May 17th, 2022
- Will we be able to check cholesterol using gene editing technology or will it be too dangerous and costly to even try? - L'Observateur - L'Observateur - May 17th, 2022
- DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients - PR Newswire - May 17th, 2022
- Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics - GlobeNewswire - May 17th, 2022
- This Gene Mutation Breaks the Immune System. Why Has It Survived? - WIRED - May 17th, 2022
- BRCA Experts Rally to Research DNA Repair for Better Breast, Ovarian and Other Cancer Treatments - Yale School of Medicine - May 17th, 2022
- AskBio to Present 11 Abstracts at Upcoming American Society of Gene and Cell Therapy's 25th Annual Meeting - PR Newswire - May 17th, 2022
- Protein linked to intellectual disability has complex role Washington University School of Medicine in St. Louis - Washington University School of... - May 17th, 2022
- CU School of Medicine Research Defines the Role of HDAC6 in Regulating Heart Stiffness - University of Colorado Anschutz Medical Campus - May 17th, 2022
- Emendo Biotherapeutics' next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related... - May 17th, 2022
- Latest Human Cells Atlas reveals more of the unknown world inside our bodies - EL PAS in English - May 17th, 2022
- Middle-East precision medicine market was estimated to be at $3,942.6 million in 2021, which is expected to grow with a CAGR of 7.37% and reach... - May 17th, 2022
- CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting -... - May 6th, 2022
- Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American... - May 6th, 2022
- Top 12 emerging gene and cell therapy technologies likely to impact patient care announced in annual Disruptive Dozen from Mass General Brigham -... - May 6th, 2022
- Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results - GlobeNewswire - May 6th, 2022
- BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia... - May 6th, 2022
- Athenex, Texas Childrens Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for... - May 6th, 2022
- The gene-edited pig heart given to a dying patient was infected with a pig virus - MIT Technology Review - May 6th, 2022
- WMIF panel: How cell and gene therapy can overcome limitations of CAR T - MedCity News - May 6th, 2022
- Promising results shown in the treatment of growth-hormone resistant dwarfism - EurekAlert - May 6th, 2022
- New treatment for infants with weakened immune systems - Sciworthy - May 6th, 2022
- Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular... - May 6th, 2022
- Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases -... - May 6th, 2022
- A very specific kind of brain cell dies off in people with Parkinson's - Science News Magazine - May 6th, 2022
- Gene Editing Tools Market by 2029 Thermofisher Scientific, CRISPR Therapeutics, Editas Medicine Queen Anne and Mangolia News - Queen Anne and... - May 6th, 2022
- Sleep deprivation may increase the risk of eye disease - Medical News Today - May 6th, 2022
- Parkinson's Foundation Announces Major Expansion of PD GENEration Study, Increasing Access to Genetic Testing and Counseling Across the US - PR... - May 3rd, 2022
- Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease - Yahoo Finance - May 3rd, 2022
- Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy... - May 3rd, 2022
- Ting, Baric Elected to American Academy of Arts & Sciences | Newsroom - UNC Health and UNC School of Medicine - May 3rd, 2022
- Global Genes and the Orphan Disease Center of the University of Pennsylvania Host 7th Annual RARE Drug Development Symposium - Yahoo Finance - May 3rd, 2022
- May 2022: Nuclear condensates' role in gene regulation, disease focus of talk - Environmental Factor Newsletter - May 3rd, 2022
- Race, ethnicity, and ancestry have no standard definitions in medicine - Sciworthy - May 3rd, 2022
- Folk Medicine Discovery Could Lead to Better Heart Attack Outcomes - The Roanoke Star - May 3rd, 2022
- Genetic breakthrough could be the key that unlocks lupus - Cosmos - May 3rd, 2022
- ASGCT Partners with PlatformQ Health to Bring Impactful, Timely Gene and Cell Therapy Digital Education to Providers and Patients - PR Web - May 3rd, 2022
- Genomics technology and the future of food security and human health - TheCable - May 3rd, 2022
- Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting - GlobeNewswire - May 3rd, 2022
- ORYZON Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University - GlobeNewswire - May 3rd, 2022
- GAO Makes MACPAC Appointments and Reappointments | US GAO - Government Accountability Office - May 3rd, 2022
- Optogenetic Gene Therapy Company Ray Therapeutics Awarded $4 Million Grant - Pulse 2.0 - May 3rd, 2022
- Does autism begin in the womb? - EurekAlert - May 3rd, 2022